Printer Friendly

Avita Trial of Recell Device Demonstrates Reduction in Donor Skin Requirements in Third-Degree Burns.

M2 PHARMA-April 18, 2018-Avita Trial of Recell Device Demonstrates Reduction in Donor Skin Requirements in Third-Degree Burns

(C)2018 M2 COMMUNICATIONS

- Valencia, California-based regenerative medicine company Avita Medical's (ASX: AVH; OTCQX: AVMXY) pivotal, controlled clinical trial in the treatment of deep full-thickness (third-degree) burns with the Recell autologous cell harvesting device has achieved its co-primary endpoints, demonstrating a statistically significant reduction in donor skin requirements versus standard of care while achieving comparable definitive wound closure, the company said.

The results, presented at the American Burn Association 50th annual meeting in Chicago, described the outcomes from the controlled clinical trial conducted at seven US burn centers.

According to the company, the Recell device is an investigational medical device designed to enable medical professionals to produce, at the point-of-care, a 'regenerative epidermal suspension' using a small sample of the patient's own skin. '

The autologous suspension contains cells necessary to regenerate epidermis and provides a new way to achieve permanent closure in burns and other wounds while reducing the amount of skin harvested at the time of surgery.

During the trial, the patient donor skin required to be harvested to treat burn sites with the Recell Device was 32% less than the amount harvested to treat burn sites with the standard of care (p

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2018 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2018 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Date:Apr 18, 2018
Words:222
Previous Article:Bristol-Myers Squibb Partners with Illumina to Develop Diagnostic Oncology Assay to Measure Predictive Genomic Biomarkers.
Next Article:Astellas Grants Exclusive License to Cardurion Pharmaceuticals to Develop Clinical Stage Heart Failure Candidate.
Topics:

Terms of use | Privacy policy | Copyright © 2021 Farlex, Inc. | Feedback | For webmasters |